ProfileGDS5678 / 1421679_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 79% 74% 73% 74% 75% 75% 74% 73% 75% 75% 74% 74% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8637274
GSM967853U87-EV human glioblastoma xenograft - Control 25.6131379
GSM967854U87-EV human glioblastoma xenograft - Control 34.8585374
GSM967855U87-EV human glioblastoma xenograft - Control 44.8292473
GSM967856U87-EV human glioblastoma xenograft - Control 54.8207274
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8750875
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8493175
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7738574
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.70573
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9829875
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9419175
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8670374
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8557574
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8444274